vs
MESA LABORATORIES INC（MLAB）与Senseonics Holdings, Inc.（SENS）财务数据对比。点击上方公司名可切换其他公司
MESA LABORATORIES INC的季度营收约是Senseonics Holdings, Inc.的4.6倍（$65.1M vs $14.3M）。MESA LABORATORIES INC净利率更高（5.6% vs -146.1%，领先151.6%）。Senseonics Holdings, Inc.同比增速更快（71.8% vs 3.6%）。MESA LABORATORIES INC自由现金流更多（$18.0M vs $-18.4M）。过去两年Senseonics Holdings, Inc.的营收复合增速更高（68.1% vs 5.1%）
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
Senseonics Holdings是一家深耕糖尿病护理领域的医疗科技企业，核心业务为研发和商业化可长期植入的连续血糖监测系统，旗下旗舰Eversense系列产品支持更长佩戴时长，已在北美、欧洲等地区上市，服务糖尿病患者及相关医疗从业者。
MLAB vs SENS — 直观对比
营收规模更大
MLAB
是对方的4.6倍
$14.3M
营收增速更快
SENS
高出68.2%
3.6%
净利率更高
MLAB
高出151.6%
-146.1%
自由现金流更多
MLAB
多$36.4M
$-18.4M
两年增速更快
SENS
近两年复合增速
5.1%
损益表 — Q3 2026 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $65.1M | $14.3M |
| 净利润 | $3.6M | $-20.8M |
| 毛利率 | 64.2% | 53.8% |
| 营业利润率 | 12.2% | -146.8% |
| 净利率 | 5.6% | -146.1% |
| 营收同比 | 3.6% | 71.8% |
| 净利润同比 | 316.6% | -34.6% |
| 每股收益（稀释后） | $0.65 | $-1.19 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MLABSENS
| Q4 25 | $65.1M | $14.3M | ||
| Q3 25 | $60.7M | $8.1M | ||
| Q2 25 | $59.5M | $6.6M | ||
| Q1 25 | $62.1M | $6.3M | ||
| Q4 24 | $62.8M | $8.3M | ||
| Q3 24 | $57.8M | $4.3M | ||
| Q2 24 | $58.2M | $4.9M | ||
| Q1 24 | $58.9M | $5.0M |
净利润MLABSENS
| Q4 25 | $3.6M | $-20.8M | ||
| Q3 25 | $2.5M | $-19.5M | ||
| Q2 25 | $4.7M | $-14.5M | ||
| Q1 25 | $-7.1M | $-14.3M | ||
| Q4 24 | $-1.7M | $-15.5M | ||
| Q3 24 | $3.4M | $-24.0M | ||
| Q2 24 | $3.4M | $-20.3M | ||
| Q1 24 | $-254.6M | $-18.9M |
毛利率MLABSENS
| Q4 25 | 64.2% | 53.8% | ||
| Q3 25 | 61.5% | 42.8% | ||
| Q2 25 | 62.0% | 46.9% | ||
| Q1 25 | 61.8% | 24.1% | ||
| Q4 24 | 63.3% | 47.6% | ||
| Q3 24 | 61.3% | -95.0% | ||
| Q2 24 | 64.0% | 6.1% | ||
| Q1 24 | 62.1% | 6.6% |
营业利润率MLABSENS
| Q4 25 | 12.2% | -146.8% | ||
| Q3 25 | 7.8% | -242.1% | ||
| Q2 25 | 5.1% | -215.4% | ||
| Q1 25 | 2.4% | -215.6% | ||
| Q4 24 | 9.2% | -172.0% | ||
| Q3 24 | 6.1% | -535.9% | ||
| Q2 24 | 9.6% | -400.7% | ||
| Q1 24 | -460.6% | -361.2% |
净利率MLABSENS
| Q4 25 | 5.6% | -146.1% | ||
| Q3 25 | 4.1% | -241.3% | ||
| Q2 25 | 8.0% | -218.1% | ||
| Q1 25 | -11.4% | -227.9% | ||
| Q4 24 | -2.7% | -186.5% | ||
| Q3 24 | 5.9% | -562.4% | ||
| Q2 24 | 5.8% | -417.0% | ||
| Q1 24 | -432.2% | -374.0% |
每股收益（稀释后）MLABSENS
| Q4 25 | $0.65 | $-1.19 | ||
| Q3 25 | $0.45 | $-0.43 | ||
| Q2 25 | $0.85 | $-0.02 | ||
| Q1 25 | $-1.30 | $-0.02 | ||
| Q4 24 | $-0.31 | $-1.67 | ||
| Q3 24 | $0.63 | $-0.77 | ||
| Q2 24 | $0.62 | $-0.03 | ||
| Q1 24 | $-47.26 | $-0.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $29.0M | $94.0M |
| 总债务越低越好 | $68.4M | $35.6M |
| 股东权益账面价值 | $186.7M | $61.0M |
| 总资产 | $434.8M | $126.3M |
| 负债/权益比越低杠杆越低 | 0.37× | 0.58× |
8季度趋势，按日历期对齐
现金及短期投资MLABSENS
| Q4 25 | $29.0M | $94.0M | ||
| Q3 25 | $20.4M | $111.0M | ||
| Q2 25 | $21.3M | $126.4M | ||
| Q1 25 | $27.3M | $64.2M | ||
| Q4 24 | $27.3M | $74.6M | ||
| Q3 24 | $24.3M | $74.5M | ||
| Q2 24 | $28.5M | $84.6M | ||
| Q1 24 | $28.2M | $98.7M |
总债务MLABSENS
| Q4 25 | $68.4M | $35.6M | ||
| Q3 25 | $69.4M | $35.3M | ||
| Q2 25 | $70.3M | $35.2M | ||
| Q1 25 | $71.3M | $35.0M | ||
| Q4 24 | $72.2M | $34.7M | ||
| Q3 24 | $73.1M | $34.4M | ||
| Q2 24 | $74.1M | $34.2M | ||
| Q1 24 | — | $34.0M |
股东权益MLABSENS
| Q4 25 | $186.7M | $61.0M | ||
| Q3 25 | $178.5M | $78.2M | ||
| Q2 25 | $172.5M | $94.7M | ||
| Q1 25 | $159.8M | $35.2M | ||
| Q4 24 | $155.2M | $-16.6M | ||
| Q3 24 | $161.5M | $-17.2M | ||
| Q2 24 | $150.7M | $578.0K | ||
| Q1 24 | $145.4M | $19.0M |
总资产MLABSENS
| Q4 25 | $434.8M | $126.3M | ||
| Q3 25 | $430.4M | $139.9M | ||
| Q2 25 | $435.7M | $150.3M | ||
| Q1 25 | $433.3M | $87.2M | ||
| Q4 24 | $433.3M | $100.4M | ||
| Q3 24 | $454.1M | $96.3M | ||
| Q2 24 | $440.4M | $111.6M | ||
| Q1 24 | $446.8M | $126.5M |
负债/权益比MLABSENS
| Q4 25 | 0.37× | 0.58× | ||
| Q3 25 | 0.39× | 0.45× | ||
| Q2 25 | 0.41× | 0.37× | ||
| Q1 25 | 0.45× | 0.99× | ||
| Q4 24 | 0.47× | — | ||
| Q3 24 | 0.45× | — | ||
| Q2 24 | 0.49× | 59.17× | ||
| Q1 24 | — | 1.79× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $18.8M | $-18.0M |
| 自由现金流经营现金流 - 资本支出 | $18.0M | $-18.4M |
| 自由现金流率自由现金流/营收 | 27.7% | -128.8% |
| 资本支出强度资本支出/营收 | 1.1% | 2.8% |
| 现金转化率经营现金流/净利润 | 5.17× | — |
| 过去12个月自由现金流最近4个季度 | $37.9M | $-60.2M |
8季度趋势，按日历期对齐
经营现金流MLABSENS
| Q4 25 | $18.8M | $-18.0M | ||
| Q3 25 | $8.2M | $-15.8M | ||
| Q2 25 | $1.9M | $-9.3M | ||
| Q1 25 | $12.7M | $-16.1M | ||
| Q4 24 | $18.1M | $-14.2M | ||
| Q3 24 | $5.3M | $-14.8M | ||
| Q2 24 | $10.7M | $-11.1M | ||
| Q1 24 | $12.9M | $-20.3M |
自由现金流MLABSENS
| Q4 25 | $18.0M | $-18.4M | ||
| Q3 25 | $7.1M | $-16.0M | ||
| Q2 25 | $884.0K | $-9.4M | ||
| Q1 25 | $11.9M | $-16.5M | ||
| Q4 24 | $17.3M | $-14.3M | ||
| Q3 24 | $3.5M | $-15.0M | ||
| Q2 24 | $9.9M | $-13.2M | ||
| Q1 24 | $12.3M | $-20.6M |
自由现金流率MLABSENS
| Q4 25 | 27.7% | -128.8% | ||
| Q3 25 | 11.7% | -197.4% | ||
| Q2 25 | 1.5% | -141.2% | ||
| Q1 25 | 19.2% | -263.9% | ||
| Q4 24 | 27.6% | -172.1% | ||
| Q3 24 | 6.0% | -352.3% | ||
| Q2 24 | 16.9% | -272.0% | ||
| Q1 24 | 21.0% | -407.7% |
资本支出强度MLABSENS
| Q4 25 | 1.1% | 2.8% | ||
| Q3 25 | 1.8% | 2.0% | ||
| Q2 25 | 1.7% | 1.9% | ||
| Q1 25 | 1.2% | 6.9% | ||
| Q4 24 | 1.3% | 0.4% | ||
| Q3 24 | 3.1% | 4.8% | ||
| Q2 24 | 1.5% | 43.0% | ||
| Q1 24 | 0.9% | 6.3% |
现金转化率MLABSENS
| Q4 25 | 5.17× | — | ||
| Q3 25 | 3.32× | — | ||
| Q2 25 | 0.40× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.54× | — | ||
| Q2 24 | 3.17× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
SENS
| Nonrelated Party | $7.8M | 55% |
| Related Party | $6.4M | 45% |
